Imaging DNA Damage Repair In Vivo After <sup>177</sup>Lu-DOTATATE Therapy
2019 · Journal of Nuclear Medicine · 46 citations
https://doi.org/10.2967/jnumed.119.232934
M
Michael Mosley
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
80
Papers
2.3K
Citations
20
h-index
27
i10-index
Michael Mosley is an academic researcher from East Carolina University. The author has contributed to research in topics: PARP inhibition in cancer therapy & Radiopharmaceutical Chemistry and Applications & Pancreatic and Hepatic Oncology Research. The author has an h-index of 20, co-authored 68 publications.
ORCID: 0000-0002-5324-4565Papers by this author
worksDual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours
2019 · Nuclear Medicine and Biology · 26 citations
https://doi.org/10.1016/j.nucmedbio.2019.01.010
Radiolabeled cCPE Peptides for SPECT Imaging of Claudin-4 Overexpression in Pancreatic Cancer
2020 · Journal of Nuclear Medicine · 24 citations
https://doi.org/10.2967/jnumed.120.243113
Imaging PARP with [18F]rucaparib in pancreatic cancer models
2022 · European Journal of Nuclear Medicine and Molecular Imaging · 23 citations
https://doi.org/10.1007/s00259-022-05835-4
In Vivo Pretargeted Imaging of HER2 and TAG-72 Expression Using the HaloTag Enzyme
2017 · Molecular Pharmaceutics · 21 citations
https://doi.org/10.1021/acs.molpharmaceut.7b00172
[18F]AZD2461, an Insight on Difference in PARP Binding Profiles for DNA Damage Response PET Imaging
2020 · Molecular Imaging and Biology · 18 citations
https://doi.org/10.1007/s11307-020-01497-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat